{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:01:25Z","timestamp":1790917285950,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Autosomal recessive polycystic kidney disease (ARPKD) is a hereditary condition characterized by massive kidney enlargement and developmental liver defects. Potential consequences during childhood include the need for kidney replacement therapy (KRT). We report the design of 2 ongoing clinical trials (Study 204, Study 307) to evaluate safety, tolerability, and efficacy of tolvaptan in children with ARPKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Both trials are of multinational, multicenter, open-label design. Age range at enrollment is 28\u00a0days to\u2009&lt;\u200912\u00a0weeks in Study 204 and 28\u00a0days to\u2009&lt;\u200918\u00a0years in Study 307. Subjects in both studies must have a clinical diagnosis of ARPKD, and those in Study 204 must additionally have signs indicative of risk of rapid progression to KRT, namely, all of: nephromegaly, multiple kidney cysts or increased kidney echogenicity suggesting microcysts, and oligohydramnios or anhydramnios. Target enrollment is 20 subjects for Study 204 and\u2009\u2265\u200910 subjects for Study 307.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Follow-up is 24\u00a0months in Study 204 (with optional additional treatment up to 36\u00a0months) and 18\u00a0months in Study 307. Outcomes include safety, tolerability, change in kidney function, and percentage of subjects requiring KRT relative to historical data. Regular safety assessments monitor for possible adverse effects of treatment on parameters such as liver function, kidney function, fluid balance, electrolyte levels, and growth trajectory, with increased frequency of monitoring following tolvaptan initiation or dose escalation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These trials will provide data on tolvaptan safety and efficacy in a population without disease-specific treatment options.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Study 204: EudraCT 2020\u2013005991-36; Study 307: EudraCT 2020\u2013005992-10.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-023-03072-x","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T14:03:53Z","timestamp":1676297033000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Design of two ongoing clinical trials of tolvaptan in the treatment of pediatric patients with autosomal recessive polycystic kidney disease"],"prefix":"10.1186","volume":"24","author":[{"given":"Djalila","family":"Mekahli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0494-9080","authenticated-orcid":false,"given":"Max C.","family":"Liebau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0460-2477","authenticated-orcid":false,"given":"Melissa A.","family":"Cadnapaphornchai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3711-8785","authenticated-orcid":false,"given":"Stuart L.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2490-021X","authenticated-orcid":false,"given":"Larry A.","family":"Greenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5241-2483","authenticated-orcid":false,"given":"Mieczyslaw","family":"Litwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Seeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7564-9937","authenticated-orcid":false,"given":"Franz","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6187-3927","authenticated-orcid":false,"given":"Lisa M.","family":"Guay-Woodford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,13]]},"reference":[{"key":"3072_CR1","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3389\/fped.2017.00080","volume":"5","author":"B Alzarka","year":"2017","unstructured":"Alzarka B, Morizono H, Bollman JW, Kim D, Guay-Woodford LM. Design and implementation of the Hepatorenal Fibrocystic Disease Core Center clinical database: a centralized resource for characterizing autosomal recessive polycystic kidney disease and other hepatorenal fibrocystic diseases. Front Pediatr. 2017;5:80. https:\/\/doi.org\/10.3389\/fped.2017.00080.","journal-title":"Front Pediatr"},{"key":"3072_CR2","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1086\/340448","volume":"70","author":"LF Onuchic","year":"2002","unstructured":"Onuchic LF, Furu L, Nagasawa Y, Hou X, Eggermann T, Ren Z, Bergmann C, Senderek J, Esquivel E, Zeltner R, et al. PKHD1, the polycystic kidney and hepatic disease 1 gene, encodes a novel large protein containing multiple immunoglobulin-like plexin-transcription-factor domains and parallel beta-helix 1 repeats. Am J Hum Genet. 2002;70:1305\u201317. https:\/\/doi.org\/10.1086%2F340448.","journal-title":"Am J Hum Genet"},{"key":"3072_CR3","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/ng.3871","volume":"49","author":"H Lu","year":"2017","unstructured":"Lu H, Galeano MCR, Ott E, Kaeslin G, Kausalya PJ, Kramer C, Ortiz-Br\u00fcchle N, Hilger N, Metzis V, Hiersche M, et al. Mutations in DZIP1L, which encodes a ciliary-transition-zone protein, cause autosomal recessive polycystic kidney disease. Nat Genet. 2017;49:1025\u201334. https:\/\/doi.org\/10.1038\/ng.3871.","journal-title":"Nat Genet"},{"key":"3072_CR4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41572-018-0047-y","volume":"4","author":"C Bergmann","year":"2018","unstructured":"Bergmann C, Guay-Woodford LM, Harris PC, Horie S, Peters DJM, Torres VE. Polycystic kidney disease. Nat Rev Dis Primers. 2018;4:50. https:\/\/doi.org\/10.1038\/s41572-018-0047-y.","journal-title":"Nat Rev Dis Primers"},{"key":"3072_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-0040-1714701","volume":"10","author":"D Wicher","year":"2021","unstructured":"Wicher D, Obrycki \u0141, Jankowska I. Autosomal recessive polycystic kidney disease-the clinical aspects and diagnostic challenges. J Pediatr Genet. 2021;10:1\u20138. https:\/\/doi.org\/10.1055\/s-0040-1714701.","journal-title":"J Pediatr Genet"},{"issue":"5 Pt 1","key":"3072_CR6","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1542\/peds.111.5.1072","volume":"111","author":"LM Guay-Woodford","year":"2003","unstructured":"Guay-Woodford LM, Desmond RA. Autosomal recessive polycystic kidney disease: the clinical experience in North America. Pediatrics. 2003;111(5 Pt 1):1072\u201380. https:\/\/doi.org\/10.1542\/peds.111.5.1072.","journal-title":"Pediatrics"},{"key":"3072_CR7","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/humu.20019","volume":"23","author":"C Bergmann","year":"2004","unstructured":"Bergmann C, Senderek J, Schneider F, Dornia C, K\u00fcpper F, Eggermann T, Rudnik-Sch\u00f6neborn S, Kirfel J, Moser M, B\u00fcttner R, et al. PKHD1 mutations in families requesting prenatal diagnosis for autosomal recessive polycystic kidney disease (ARPKD). Hum Mutat. 2004;23:487\u201395. https:\/\/doi.org\/10.1002\/humu.20019.","journal-title":"Hum Mutat"},{"key":"3072_CR8","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1007\/s00467-021-04970-8","volume":"36","author":"MC Liebau","year":"2021","unstructured":"Liebau MC. Early clinical management of autosomal recessive polycystic kidney disease. Pediatr Nephrol. 2021;36:3561\u201370. https:\/\/doi.org\/10.1007\/s00467-021-04970-8.","journal-title":"Pediatr Nephrol"},{"key":"3072_CR9","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1053\/j.ajkd.2016.06.019","volume":"68","author":"D Mekahli","year":"2016","unstructured":"Mekahli D, van Stralen KJ, Bonthuis M, Jager KJ, Balat A, Benetti E, Godefroid N, Edvardsson VO, Heaf JG, Jankauskiene A, ESPN\/ERA-EDTA Registry, et al. Kidney versus combined kidney and liver transplantation in young people with autosomal recessive polycystic kidney disease: data from the European Society for Pediatric Nephrology\/European Renal Association-European Dialysis and Transplant (ESPN\/ERA-EDTA) Registry. Am J Kidney Dis. 2016;68:782\u20138. https:\/\/doi.org\/10.1053\/j.ajkd.2016.06.019.","journal-title":"Am J Kidney Dis."},{"key":"3072_CR10","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/j.1523-1755.2005.00148.x","volume":"67","author":"C Bergmann","year":"2005","unstructured":"Bergmann C, Senderek J, Windelen E, K\u00fcpper F, Middeldorf I, Schneider F, Dornia C, Rudnik-Sch\u00f6neborn S, Konrad M, Schmitt CP, APN (Arbeitsgemeinschaft f\u00fcr P\u00e4diatrische Nephrologie), et al. Clinical consequences of PKHD1 mutations in 164 patients with autosomal-recessive polycystic kidney disease (ARPKD). Kidney Int. 2005;67:829\u201348. https:\/\/doi.org\/10.1111\/j.1523-1755.2005.00148.x.","journal-title":"Kidney Int"},{"key":"3072_CR11","doi-asserted-by":"publisher","first-page":"972","DOI":"10.2215\/cjn.07141009","volume":"5","author":"M Gunay-Aygun","year":"2010","unstructured":"Gunay-Aygun M, Font-Montgomery E, Lukose L, Tuchman M, Graf J, Bryant JC, Kleta R, Garcia A, Edwards H, Piwnica-Worms K, et al. Correlation of kidney function, volume and imaging findings, and PKHD1 mutations in 73 patients with autosomal recessive polycystic kidney disease. Clin J Am Soc Nephrol. 2010;5:972\u201384. https:\/\/doi.org\/10.2215\/cjn.07141009.","journal-title":"Clin J Am Soc Nephrol"},{"key":"3072_CR12","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.kint.2021.04.019","volume":"100","author":"K Burgmaier","year":"2021","unstructured":"Burgmaier K, Brinker L, Erger F, Beck BB, Benz MR, Bergmann C, Boyer O, Collard L, Dafinger C, Fila M, ESCAPE Study group, GPN study group, D\u00f6tsch J, Schaefer F, Liebau MC, ARegPKD consortium, et al. Refining genotype-phenotype correlations in 304 patients with autosomal recessive polycystic kidney disease and PKHD1 gene variants. Kidney Int. 2021;100:650\u20139. https:\/\/doi.org\/10.1016\/j.kint.2021.04.019.","journal-title":"Kidney Int"},{"key":"3072_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jpeds.2018.03.052","volume":"199","author":"K Burgmaier","year":"2018","unstructured":"Burgmaier K, Kunzmann K, Ariceta G, Bergmann C, Buescher AK, Burgmaier M, Dursun I, Duzova A, Eid L, Erger F, ESCAPE Study Group, GPN Study Group, D\u00f6tsch J, Schaefer F, Liebau MC, ARegPKD consortium, et al. Risk factors for early dialysis dependency in autosomal recessive polycystic kidney disease. J Pediatr. 2018;199:22-28.e6. https:\/\/doi.org\/10.1016\/j.jpeds.2018.03.052.","journal-title":"J Pediatr"},{"key":"3072_CR14","doi-asserted-by":"publisher","first-page":"21677","DOI":"10.1038\/s41598-021-00523-z","volume":"11","author":"K Burgmaier","year":"2021","unstructured":"Burgmaier K, Kilian S, Arbeiter K, Atmis B, B\u00fcscher A, Derichs U, Dursun I, Duzova A, Eid LA, Galiano M, ARegPKD Consortium, et al. Early childhood height-adjusted total kidney volume as a risk marker of kidney survival in ARPKD. Sci Rep. 2021;11:21677. https:\/\/doi.org\/10.1038\/s41598-021-00523-z.","journal-title":"Sci Rep"},{"key":"3072_CR15","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1681\/asn.v1171179","volume":"11","author":"K Hanaoka","year":"2000","unstructured":"Hanaoka K, Guggino WB. cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. J Am Soc Nephrol. 2000;11:1179\u201387. https:\/\/doi.org\/10.1681\/asn.v1171179.","journal-title":"J Am Soc Nephrol"},{"key":"3072_CR16","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1046\/j.1523-1755.2000.00991.x","volume":"57","author":"T Yamaguchi","year":"2000","unstructured":"Yamaguchi T, Pelling JC, Ramaswamy NT, Eppler JW, Wallace DP, Nagao S, Rome LA, Sullivan LP, Grantham JJ. cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int. 2000;57:1460\u201371. https:\/\/doi.org\/10.1046\/j.1523-1755.2000.00991.x.","journal-title":"Kidney Int"},{"issue":"1","key":"3072_CR17","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1681\/asn.2007060688","volume":"19","author":"X Wang","year":"2008","unstructured":"Wang X, Wu Y, Ward CJ, Harris PC, Torres VE. Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol. 2008;19(1):102\u20138. https:\/\/doi.org\/10.1681\/asn.2007060688.","journal-title":"J Am Soc Nephrol"},{"key":"3072_CR18","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00467-017-3672-x","volume":"33","author":"P Janssens","year":"2018","unstructured":"Janssens P, Weydert C, De Rechter S, Wissing KM, Liebau MC, Mekahli D. Expanding the role of vasopressin antagonism in polycystic kidney diseases: from adults to children? Pediatr Nephrol. 2018;33:395\u2013408. https:\/\/doi.org\/10.1007\/s00467-017-3672-x.","journal-title":"Pediatr Nephrol"},{"key":"3072_CR19","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/nm935","volume":"9","author":"VH Gattone 2nd","year":"2003","unstructured":"Gattone VH 2nd, Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med. 2003;9:1323\u20136. https:\/\/doi.org\/10.1038\/nm935.","journal-title":"Nat Med"},{"key":"3072_CR20","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/nm1004","volume":"10","author":"VE Torres","year":"2004","unstructured":"Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH 2nd. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med. 2004;10:363\u20134. https:\/\/doi.org\/10.1038\/nm1004.","journal-title":"Nat Med"},{"key":"3072_CR21","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1681\/asn.2004121090","volume":"16","author":"X Wang","year":"2005","unstructured":"Wang X, Gattone V 2nd, Harris PC, Torres VE. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol. 2005;16:846\u201351. https:\/\/doi.org\/10.1681\/asn.2004121090.","journal-title":"J Am Soc Nephrol"},{"key":"3072_CR22","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1093\/ndt\/gfr069","volume":"26","author":"E Meijer","year":"2011","unstructured":"Meijer E, Gansevoort RT, de Jong PE, van der Wal AM, Leonhard WN, de Krey SR, van den Born J, Mulder GM, van Goor H, Struck J, et al. Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug. Nephrol Dial Transplant. 2011;26:2445\u201353. https:\/\/doi.org\/10.1093\/ndt\/gfr069.","journal-title":"Nephrol Dial Transplant"},{"key":"3072_CR23","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/nejmoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS, TEMPO 3:4 Trial Investigators. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407\u201318. https:\/\/doi.org\/10.1056\/nejmoa1205511.","journal-title":"N Engl J Med"},{"key":"3072_CR24","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/nejmoa1710030","volume":"377","author":"VE Torres","year":"2017","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS, REPRISE Trial Investigators, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377:1930\u201342. https:\/\/doi.org\/10.1056\/nejmoa1710030.","journal-title":"N Engl J Med"},{"key":"3072_CR25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2215\/CJN.0000000000000022","volume":"18","author":"D Mekahli","year":"2023","unstructured":"Mekahli D, Guay-Woodford LM, Cadnapaphornchai MA, Greenbaum LA, Litwin M, Seeman T, Dandurand A, Shi L, Sikes K, Shoaf SE, et al. Tolvaptan for children and adolescents with autosomal dominant polycystic kidney disease: randomized controlled trial. Clin J Am Soc Nephrol. 2023;18:36\u201346. https:\/\/doi.org\/10.2215\/CJN.0000000000000022.","journal-title":"Clin J Am Soc Nephrol"},{"key":"3072_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40348-021-00131-x","volume":"8","author":"MC Liebau","year":"2021","unstructured":"Liebau MC, Mekahli D. Translational research approaches to study pediatric polycystic kidney disease. Mol Cell Pediatr. 2021;8:20. https:\/\/doi.org\/10.1186\/s40348-021-00131-x.","journal-title":"Mol Cell Pediatr"},{"key":"3072_CR27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12882-015-0002-z","volume":"16","author":"K Ebner","year":"2015","unstructured":"Ebner K, Feldkoetter M, Ariceta G, Bergmann C, Buettner R, Doyon A, Duzova A, Goebel H, Haffner D, Hero B, ESCAPE Study Group, GPN Study Group, et al. Rationale, design and objectives of ARegPKD, a European ARPKD registry study. BMC Nephrol. 2015;16:22. https:\/\/doi.org\/10.1186\/s12882-015-0002-z.","journal-title":"BMC Nephrol"},{"key":"3072_CR28","unstructured":"ARPKDB: Autosomal Recessive Polycystic Kidney Disease database. https:\/\/arpkdb.org\/. Accessed 28 Nov 2022."},{"key":"3072_CR29","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/j.1365-2125.2011.04114.x","volume":"73","author":"SE Shoaf","year":"2012","unstructured":"Shoaf SE, Bricmont P, Mallikaarjun S. Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects. Br J Clin Pharmacol. 2012;73:579\u201387. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.04114.x.","journal-title":"Br J Clin Pharmacol"},{"key":"3072_CR30","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2165\/00003088-199937060-00004","volume":"37","author":"SN de Wildt","year":"1999","unstructured":"de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet. 1999;37:485\u2013505. https:\/\/doi.org\/10.2165\/00003088-199937060-00004.","journal-title":"Clin Pharmacokinet"},{"key":"3072_CR31","unstructured":"JYNARQUE [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical, Inc.; 2020. https:\/\/www.otsuka-us.com\/sites\/g\/files\/qhldwo4671\/files\/media\/static\/JYNARQUE-PI.pdf. Accessed 14 Nov\u00a02022."},{"key":"3072_CR32","unstructured":"United States Food and Drug Administration. Guidance for industry, drug-induced liver injury: premarketing clinical evaluation. 2009. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM174090.pdf. Accessed 11 July 2022."},{"key":"3072_CR33","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3389\/fped.2017.00221","volume":"5","author":"C Bergmann","year":"2018","unstructured":"Bergmann C. Genetics of autosomal recessive polycystic kidney disease and its differential diagnoses. Front Pediatr. 2018;5:221. https:\/\/doi.org\/10.3389\/fped.2017.00221.","journal-title":"Front Pediatr"},{"key":"3072_CR34","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40264-015-0327-3","volume":"38","author":"PB Watkins","year":"2015","unstructured":"Watkins PB, Lewis JH, Kaplowitz N, Alpers DH, Blais JD, Smotzer DM, Krasa H, Ouyang J, Torres VE, Czerwiec FS, et al. Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database. Drug Saf. 2015;38:1103\u201313. https:\/\/doi.org\/10.1007\/s40264-015-0327-3.","journal-title":"Drug Saf"},{"issue":"22","key":"3072_CR35","doi-asserted-by":"publisher","first-page":"00921","DOI":"10.1053\/j.ajkd.2022.08.012","volume":"S0272\u20136386","author":"DH Alpers","year":"2022","unstructured":"Alpers DH, Lewis JH, Hunt CM, Freston JW, Torres VE, Li H, Wang W, Hoke ME, Roth SE, Westcott-Baker L, et al. Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease (ADPKD): analysis of pivotal clinical trials. Am J Kidney Dis. 2022;S0272\u20136386(22):00921. https:\/\/doi.org\/10.1053\/j.ajkd.2022.08.012. Epub ahead of print.","journal-title":"Am J Kidney Dis"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03072-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-023-03072-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03072-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T01:16:52Z","timestamp":1676337412000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-023-03072-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,13]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3072"],"URL":"https:\/\/doi.org\/10.1186\/s12882-023-03072-x","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,13]]},"assertion":[{"value":"13 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial is being performed in compliance with International Council for Harmonization Good Clinical Practice guidance, international ethical principles derived from the Declaration of Helsinki and Council for International Organizations of Medical Science guidelines, and applicable local laws and regulations. Each trial site must obtain approval\/favorable opinion by an institutional review board or independent ethics committee according to regional requirements. The institutional review boards that have issued approvals to date for Study 204 are: WCG IRB \u2013 Puyallup, WA; and Cincinnati Children\u2019s Hospital Institutional Review Board \u2013 Cincinnati, OH. The institutional review boards that have issued approvals to date for Study 307 are: WCG IRB \u2013 Puyallup, WA; Advarra IRB \u2013 Columbia, MD; and Cincinnati Children\u2019s Hospital Institutional Review Board \u2013 Cincinnati, OH.Informed consent is obtained from all subjects\u2019 parents or their legal guardians. In Study 307, written informed assent is obtained from all subjects old enough per local laws to provide assent. Age-appropriate assent documents were created and subjects who are able are required to reconsent or assent as appropriate if they matriculate from one age group to another.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DM serves on an advisory board of Otsuka Pharmaceuticals, Sanofi Genzyme and Reata as a representative of the University Hospital of Leuven and has received educational grants from Otsuka Pharmaceuticals paid to the University Hospital of Leuven. All of these activities are outside the submitted work.MCL serves on an advisory board of Otsuka Pharmaceuticals as a representative of the University Hospital of Cologne.MAC serves on a pediatric advisory board of Otsuka Pharmaceuticals Inc.SLG has received grant funding from and served as a consultant for Otsuka.LAG is a consultant for and receives research support from Otsuka Pharmaceuticals.ML reports consulting for Otsuka.TS reports consulting for Otsuka.FS reports consulting for Otsuka.LMGW serves a consultant for and receives honoraria from Otsuka and Natera, Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}